Table 2 Analysis and quality of the evidence using GRADE for efficacy and safety outcomes
Outcomes | No of participants (studies) | Relative effect (95% CI) | Risk of bias | Inconsistency | Indirectness | Imprecision | Publication bias | Quality of the evidence (GRADE) |
|---|---|---|---|---|---|---|---|---|
1. Subgroup Analysis - Cilostazol compared to Aspirin for the Secondary Prevention of Stroke in the Chronic phase | ||||||||
ROCI | 3459 (3 studies) | RR 0.82 (0.62 to 1.08) | No serious | No serious | No serious | No serious | Undetected | ⊕ ⊕ ⊕ ⊕ high |
HSSH | 3459 (3 studies) | RR 0.29 (0.15 to 0.56)*** | No serious | No serious | No serious | No serious | Undetected | ⊕ ⊕ ⊕ ⊕ high |
ACD | 3459 (3 studies) | RR 0.80 (0.42 to 1.53) | No serious | No serious | No serious | No serious | Undetected | ⊕ ⊕ ⊕ ⊕ high |
2. Sensitivity Analysis - Cilostazol compared to Aspirin for the Secondary Prevention of Stroke in the Chronic phase without CSPS 2 trial | ||||||||
ROCI | 787 (2 studies) | RR 0.81 (0.40 to 1.66) | Serious1 | No serious | No serious | No serious | Undetected | ⊕ ⊕ ⊕⊝ moderate |
HSSH | 787 (2 studies) | RR 0.18 (0.03 to 0.99)* | Serious1 | No serious | No serious | No serious | Undetected | ⊕ ⊕ ⊕⊝ moderate |
ACD | 787 (2 studies) | RR 0.47 (0.13 to 1.64) | Serious1 | No serious | No serious | No serious | Undetected | ⊕ ⊕ ⊕⊝ moderate |
3. Sensitivity Analysis - Cilostazol compared to Aspirin for the Secondary Prevention of Stroke in the Chronic phase without Guo-2009 trail | ||||||||
ROCI | 3391 (2 studies) | RR 0.80 (0.61 to 1.07) | No serious | No serious | No serious | No serious | Undetected | ⊕ ⊕ ⊕ ⊕ high |
HSSH | 3391 (2 studies) | RR 0.29 (0.15 to 0.56)*** | No serious | No serious | No serious | No serious | Undetected | ⊕ ⊕ ⊕ ⊕ high |
ACD | 3391 (2 studies) | RR 0.89 (0.45 to 1.73) | No serious | No serious | No serious | No serious | Undetected | ⊕ ⊕ ⊕ ⊕ high |